

THIS IS ZINZINO

Zinzino is a global D2C company from Scandinavia specialising in biomarker-based personalised dietary supplements and health technology. It is a limited liability company with shares listed on the Nasdaq First North Premier Growth Market. The company's test-based and scientifically proven supplements are available in more than 100 markets worldwide. Zinzino owns the Norwegian research and production units BioActive Foods AS and Faun Pharma AS. The company's head office is located in Gothenburg, Sweden, with additional offices in Finland, Latvia, Norway, USA, Australia, Hong Kong, Malaysia and India.

A BRIEF HISTORY

- 2007 Zinzino AB was started. The company's principal business is to own and develop companies in direct sales and related activities.
- 2009 Zinzino Nordic AB was acquired partly through a directed non-cash share issue to the owners of Zinzino Nordic AB and partly through a subscription in the preferential rights issue that Zinzino Nordic AB carried out in December. Through this, Zinzino AB obtained control over 97% of the votes and 92% of the capital of Zinzino Nordic AB. By 31 December 2021, participating interest had increased to 93% of capital.
- 2010 Zinzino shares were listed for trading on the Aktietorget stock market.
- 2011 The group was expanded with companies in Estonia and Lithuania.
- 2012 Companies were started in Latvia and Iceland.
- 2013 A company was started in the US.
- 2014 The group was further expanded by companies in Poland and the Netherlands. In the same year, Zinzino AB acquired BioActive Foods AS and 85% of the shares in Faun Pharma AS. Zinzino AB was listed for trading on Nasdaq OMX First North.
- 2015 A company was started in Canada and the ownership share in Faun Pharma AS was increased to 98.8%.
- 2016 A subsidiary was started in Germany.

 Sales were launched in all of the EU countries.
- 2017 Sales were launched in Switzerland.
- 2018 New subsidiaries in Romania and Italy.
- 2019 New subsidiaries in Australia and India.
- 2020 Acquisition of VMA Life in Singapore.
 Zinzino AB moves up to the premier segment of the
 Nasdaq First North Premier Growth Market.
- 2021 Sales were launched in South Africa.



ZINZINO YEAR-END REPORT | **2021**

OCTOBER-DECEMBER

- Total revenues increased by 18% to SEK 401.2 (340.4) million
- Gross profit was SEK 113.7 (110.2) million and gross profit margin was 28.3% (32.4%)
- EBITDA was SEK 26.4 (37.4) million and EBITDA margin was 6.6% (11.0%)
- Cash flow from operating activities was SEK 59.5 (32.9) million
- Sales launch in South Africa
- · Launch of new test concept for vitamin D

JANUARY - DECEMBER

- Total revenues increased by 20% to SEK 1,370.6 (1,138.6) million
- Gross profit amounted to SEK 427.5 (348.6*) million and the gross profit margin was 31.2% (30.6%*)
- Adjusted gross profit amounted to SEK 427.5 (326.4*) million and the adjusted gross profit margin was 31.2% (28.7%*)
- EBITDA amounted to SEK 137.6 (108.5*) million and the EBITDA margin was 10.0% (9.5%*)
- Adjusted EBITDA amounted to SEK 137.6 (86.3*) million and the adjusted EBITDA margin was 10.0% (7.6%*)
- Cash flow from operating activities amounted to SEK 153.5 (97.3) million.
- The Board of Directors proposes a dividend to shareholders for 2021 of SEK 2.00 (1.25) per share.
- Liquid assets on the balance sheet date were SEK 235.7 (143.2) million

*For comparative figures for January-December 2020, gross profit and EBITDA are impacted by SEK 22.2 million through changed accounting as a result of changed terms for distributor remuneration.

20% GROWTH AND STRONG PROFITABILITY



Dag Bergheim Pettersen, CEO, Zinzino

Zinzino continues to grow combined with good profitability.

The fourth quarter of 2021 was strong in terms of sales, with revenues up 18% overall. We also showed our strength by carrying out several important promotions with our distributors to stimulate their activity and the underlying growth going forward, while maintaining our profitability at an acceptable level.

The full year 2021 delivered 20% growth over the previous year and 10% EBITDA, fully in line with our previously upgraded forecasts. It also means that we can propose a dividend of SEK 2 per share to the upcoming annual meeting, which I think sends a really strong message. We are of course very pleased with the continued good performance and we look forward to the future.


FOCUS ON GROWTH

We are a growth company with the objective of increasing our revenues by an average of at least 20% annually in the coming years. Although we have had a slightly flatter growth curve in recent months compared to last year, we have focused on growth for new and existing markets and launched some exciting new products.

We have gradually opened up new markets in recent years. In the fourth quarter of 2021, we started sales in South Africa, which achieved full market status at Zinzino. In total, we now have sales in an entire 40 markets around the world and have a global webshop for an additional 65 countries. We work with a long-term establishment strategy that is both sustainable and balanced.

Zinzino is building a strong brand in test-based supplements and we are developing high quality products in our own production unit. During the fourth quarter, we launched two new products: our new Vitamin D Test and a magnesium and vitamin D product we call ZinoShine+.

Extensive studies at a global level show that people all over the world are very committed to their health. This has become a global trend, not least because of the current pandemic. This gives us a strong belief in the future as safe and sustainable solutions in preventive health care are increasingly in demand.



Zinzino.com

DIGITALISATION AND E-COMMERCE

Digitalisation and the increase in e-commerce are a growing global trend that we're greatly benefiting from, which we're seeing in our sales growth and healthy profitability. Zinzino has already invested and will continue to invest significant capital and resources in e-commerce.

Our vision is to inspire people all over the world to improve their lives. A stated milestone is reaching 1 million customers by 2025, which we believe we will reach sooner as we already have over 400,000 customers in our customer register. It's a constant balancing act of working towards our long-term visions and clear goals and doing a good job on a daily basis.

Our strategy is clear to everyone involved with Zinzino; employees, distributors and suppliers alike. We work with a structured and process-oriented approach with the aim of implementing all our strategic plans. The plans for this year and next are to open in more strategic markets, launch a number of new products and develop our e-commerce. We are also looking for potential companies to acquire or invest in to strengthen our global growth. Profitable growth is one of our most important strategic goals and what really inspires all of us who work with Zinzino.

Dag Bergheim Pettersen

CEO Zinzino Inspire Change in Life



FINANCIAL SUMMARY (SEKMILLION)

Key group figures	01/10/2021 31/12/2021	01/10/2020 31/12/2020	01/01/2021 31/12/2021	01/01/2020 31/12/2020
Total revenue	401.2	340.4	1,370.6	1,138.6
Net sales	372.6	323.1	1,288.5	1,074.4
Sales growth	18%	44%	20%	48%
Gross profit	113.7	110.2	427.5	348.6
Gross profit margin	28.3%	32.4%	31.2%	30.6%
Operating profit before depreciation and amortisation	26.4	37.4	137.6	108.5
Operating margin before depreciation and amortisation	6.6%	11.0%	10.0%	9.5%
Adjusted operating profit before depreciation and amortisation*	26.4	37.4	137.6	86.3
Adjusted operating margin before depreciation and amortisation*	6.6%	11.0%	10.0%	7.6%
Operating profit	20.8	31.0	116.0	86.6
Operating margin	5.2%	9.1%	8.5%	7.6%
Profit/loss before tax	20.5	31.2	114,9	85.0
Net profit	14.5	24,0	89.7	66.3
Net margin	3.6%	7.1%	6.5%	5.8%
Net earnings per share after tax before dilution, SEK	0.43	0.71	2.57	1.96
Net earnings per share after tax at full dilution, SEK				2011
	0.41	0.67	2.46	1.88
Cash flow from operating activities	59.5	32.9	153.5	97.3
Cash and cash equivalents	235.7	143.2	235.7	143.2
Equity/assets ratio	25.1%	19.6%	25.1%	19.6%
Equity per share before dilution, SEK	4.50	2.86	4.52	2.88
Number of issued shares on average for the period	33,696,682	33,043,438	33,551,514	32,860,203
Average number of issued shares for the period with full dilution	35,100,145	34,776,661	35,092,535	34,300,203

^{*}For comparative figures for January-December 2020, gross profit, operating profit before and after depreciation/ amortisation are affected by SEK 22.2 million through changed accounting as a result of changed terms for distributor remuneration. Net profit was affected by SEK 17.4 million.


ZINZINO'S OUTLOOK AND FINANCIAL GOALS FOR 2022

The Zinzino board of directors forecasts that the total revenue will exceed SEK 1,500 (1,371) million. The operating margin before depreciation is expected to exceed 7%.

The average growth in sales at Zinzino for the period 2022–2025 will be a minimum of 20% and operating margin before depreciation/amortisation will increase to over 9%. The dividend policy shall be at least 50% of the Group's net profit as long as liquidity and the equity/assets ratio allow.

SIGNIFICANT EVENTS

DURING AND AFTER THE FOURTH QUARTER OF 2021



Lions Head, Cape Town, South Africa

LAUNCH OF NEW TEST CONCEPT FOR VITAMIN D

In October 2021, Zinzino launched a new product concept for vitamin D with the introduction of the new products Vitamin D Test and ZinoShine+. Vitamin D Test is a dry blood test that anonymously analyses a person's vitamin D status. The analysis is carried out by Vitas Analytical Services - an independent GMP-certified laboratory in Norway that is a world leader in dry blood testing. Based on the results, advice is provided on whether the person should increase, decrease or maintain their vitamin D status. As the absorption of vitamin D from the sun is influenced by both seasonal and individual factors, Zinzino recommends continuous testing of vitamin D status. Zinzino has developed ZinoShine+ in order to help people adjust their vitamin D intake based on test results. ZinoShine+ is an all-natural dietary supplement containing vegan vitamin D₃ combined with magnesium. The dose of 12.5 mcg vitamin D_3 per tablet allows for an individualised vitamin D intake to maintain optimal vitamin D levels all year round.

SALES START IN SOUTH AFRICA IN NOVEMBER

After a thorough and intensive establishment process, sales under the local flag in South Africa started on 9 November 2021, which was celebrated via a simultaneous digital launch event. South Africa is Zinzino's first establishment on the African continent. Zinzino has been working on the establishment in South Africa for several years through an industry consultant. A local organisation has been built up which, at the start of sales, consisted of 285 distributors and a customer base of around 3,000 customers. The logistics are handled via a 3PL solution, in South Africa via the provider Expeditors in Johannesburg. Customer support will be handled from the head office in Gothenburg together with the industry consultant who was contracted as sales manager for South Africa and the entire African continent.

SEVERAL ONGOING NEW ESTABLISHMENT PROCESSES WITH PLANNED LAUNCH IN 2022

During the quarter, Zinzino continued to work on the establishment processes in a large number of markets around the world. On 3 February 2022, Belgium and Ireland were granted full market status with locally adapted marketing materials and payment solutions. The next planned launch will be Singapore via the company acquired through VMA Life in 2020. This will make it the fourth VMA Life company to achieve full Zinzino market status. The sales launch for Singapore will tentatively be in the second guarter of 2022. In parallel, establishment processes are underway in Russia, Ukraine, the Philippines, Mexico and Serbia, among others. Establishing a presence in these markets also requires the development of payment solutions that are compatible and certified for each market. Zinzino is thus working on the development of payment solutions that meet these requirements, which will be a key part of the expansion process in 2022.




Zinzino Vitamin D Concept

2021 **Q4** SALES AND PROFIT


SALES Q4

In total, revenue for the fourth quarter of 2021 amounted to SEK 401.2 (340.4) million, which represented a growth of 18% compared to the same period the previous year.

GROWTH PER REGION Q4 2021 VS Q4 2020



SALES PER REGION Q4



COUNTRIES IN REGIONS:

NORDIC COUNTRIES
Denmark, Faroe Islands, Finland, Iceland, Norway, Sweden

BALTIC COUNTRIES

Estonia, Latvia, Lithuania

CENTRAL EUROPE

Austria, Germany, Switzerland

EASTERN EUROPE

Czech Republic, Slovakia, Hungary, Poland, Romania

SOUTHERN & WESTERN EUROPECyprus, France, Greece, Italy, Netherlands, Spain, UK

NORTH AMERICA Canada, USA

Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand

AFRICA South Africa

NORDIC COUNTRIES

In the Nordic countries, total revenues decreased by 6% to SEK 98.9 (104.7) million in the fourth quarter of 2021 compared to the same period last year. During the quarter, the focus has been on launching the new vitamin D concept in order to attract new customers and distributor groups. Unfortunately, most planned local events have had to be cancelled due to the change in the pandemic, which has slowed down activity among distributors with reduced new sales, mainly in Denmark and Finland.

However, the decline in revenues from new recruitments was well offset by the high proportion of subscription sales from the large existing customer base in the mature markets of the region. The sales manager for the Nordic countries together with the rest of the team, will continue to support these markets from the head office with activities within sales and marketing.

Faun Pharma AS, the Group's subsidiary and manufacturing unit, reduced external production in the fourth quarter following high internal production combined with planned maintenance at the factory. Overall, this resulted in external sales decreasing by 14% to SEK 15.1 (17.7) million compared to the same period last year.

Overall, total revenues in the Nordic countries, Zinzino and Faun combined, accounted for 28% (36%) of the Group's total revenues in the fourth quarter of 2021.

THE BALTIC COUNTRIES

In the Baltic countries, revenues increased by 25% to SEK 27.0 (21.5) million in the fourth guarter of 2021 compared to the same period last year. This follows very good growth in Lithuania and Estonia. Estonia had its best sales quarter in a very long time due to high distributor activity following a good response to the quarter's sales promotions. In Latvia, the inflow of new customers and distributors decreased, but revenues were supported by high subscription sales from the large existing customer base. Overall, the Baltic countries accounted for 7% (6%) of the Group's total revenues in the fourth guarter of 2021.

To stimulate activity among distributors in the region, several local events, in the form of both digital and physical marketing activities, were planned for the fourth quarter. The head office continues to support the local sales organisations in the relatively mature markets of the region.

CENTRAL EUROPE

Good growth was seen in Germany, Austria and Switzerland during the fourth quarter of 2021. The experienced distributor organisation has continued to run its operations with high levels of efficiency and a strong focus on the positive effects of the products on the very health-conscious customer base. In the fourth quarter of 2021, total revenues increased by 31% compared to the same period last year to SEK 70.2 (53.7) million following generally high activity among distributors combined with high subscription revenues. This represented 17% (16%) of the Group's total revenues in the fourth quarter of 2021. Zinzino has high hopes that the new vitamin D concept also will attract the highly health-conscious customer base in the region in the future.

EASTERN EUROPE

Total revenues in the region in the fourth quarter of 2021 amounted to SEK 99.1 (85.0) million, representing 17% growth compared to the same period last year. The performance in the Czech Republic, Slovakia and Poland continued to be very strong, with many new customers and distributors. The markets are run by a common cluster of distributors working in an organised way across national borders which drives this growth in the region. The Hungarian market continued to decline in new sales but combined this with high revenues based on the large subscriber base in the country. Overall, Eastern Europe accounted for 25% (25%) of the Group's total revenues in the fourth quarter of 2021.

SOUTHERN & WESTERN EUROPE

Total revenues for the region in the fourth quarter of 2021 amounted to SEK 44.2 (31.5) million, representing a growth of 40% compared to the corresponding period last year.

Continued good performance in most of the countries of the region where the local sales managers support the local distributor organisations by coordinating distributor meetings and dialogue with the head office in Sweden. The strategy to get distributors back in the field has slowed down during the quarter as the pandemic once again took a grip in Europe. Despite the increasing restrictions, distributor activity has been at a consistently high level with many digital events and smaller local events, which in turn has driven the growth of new customers and expanding customer bases, driving the important customer subscription revenues. The region accounted for 11% (9%) of the Group's total revenues for the fourth quarter of 2021.

NORTH AMERICA

Revenues in North America increased by 33% to SEK 15.2 (11.5) million in the fourth quarter of 2021 compared with the previous year. This follows relatively high distributor activity in both the US and Canada with a strong focus on expanding the customer base and the important associated subscription revenues. North America accounted for 4% (4%) of the Group's total revenues in the fourth quarter of 2021.

ΔΡΔΟ

The APAC region has been the fastest growing region for Zinzino in 2021. Revenues in the APAC region during the fourth quarter of 2021 increased by 105% to a total SEK 30.4 (14.8) million. This was mainly due to a rapid increase in distributor activity and a strong influx of customers in the new markets in Asia. At the same time, good performance has continued to be seen in the part of the region that was previously handled through Zinzino's global webshop, pending the opening of markets under their own local flags.

Zinzino continues to support the building of local sales organisations through the regional offices in Adelaide, Hong Kong, Singapore and Kuala Lumpur. In the fourth quarter of 2021, the region's sales were also affected by severe shutdowns and restrictions due to the current pandemic. In this situation, the distributors worked closely with Zinzino employees where the focus was on educating new distributors on the Zinzino business model and the benefits of the products themselves. During the build-up of the region, this involves daily digital training to meet demand during the intensive growth phase. Overall, the region accounted for 8% (4%) of the Group's total revenues in the fourth quarter of 2021.

AFRICA


Sales started locally in South Africa on 9 November 2021. South Africa is Zinzino's first establishment on the African continent. The focus during the quarter has been to build on the local distributor organisation, which at the start of sales consisted of 285 distributors and a customer base of approximately 3,000 customers. During the fourth quarter, revenues amounted to SEK 1.1 (0.0) million for the African region including the revenues for the other countries in the region which, as before, are handled via Zinzino's global webshop in anticipation of the markets opening under their own local flags.

SALES PER PRODUCT SEGMENT Q4

The Zinzino Health product segment increased in the fourth quarter of 2021 by 19% to SEK 350.0 (295.2) million and represented 87% (87%) of total revenue. The Zinzino Coffee product area decreased by 28% to SEK 5.6 (7.8) million, which corresponded to 1% (2%) of total revenue. External sales in Faun Pharma AS decreased by 15% compared to the corresponding period last year, following high internal production during the quarter, and amounted to SEK 15.1 (17.7) million, which corresponded to 4% (5%) of total revenues. Other revenue amounted to SEK 30.5 (19.7) million, which corresponded to the remaining 8% (6%) of revenue for the fourth quarter of 2021.

Sales **401.2** (340.4)

SALES PER PRODUCT AREA Q4



RESULTS AND FINANCIAL POSITION Q4

PROFIT

Gross profit for the fourth quarter of 2021 amounted to SEK 113.7 (110.2) million and the gross profit margin to 28.3% (32.4%). The lower gross margin for the quarter was mainly attributable to the temporary increase in costs for goods, shipping and distributor remuneration related to this year's very successful Black Friday promotion in terms of sales. The promotion was carried out at the end of November to stimulate partner recruitment and new customers in the various sales regions. The promotion temporarily reduced profitability in the fourth quarter, but Zinzino considers the measures necessary to stimulate the activity of the local sales organisations, which slowed down during the pandemic.



The Group's operating profit before depreciation/ amortisation amounted to SEK 26.4 (37.4) million and the EBITDA margin was 6.6% (11.0%). The margin decline was entirely due to the temporary deterioration in gross profitability in the fourth quarter.


Operating profit amounted to SEK 20.8 (31.0) million and the operating margin was 5.2% (9.1%). Profit before tax totalled SEK 20.5 (31.2) million and net profit was SEK 14.5 (24.0) million.

DEPRECIATION AND AMORTISATION

Depreciation and amortisation were charged to the profit for the period in the amount of SEK 5.6 (6.5) million, of which SEK 0.6 (0.3) million was depreciation of tangible fixed assets and SEK 5.0 (6.2) million was amortisation of intangible fixed assets. Of this, SEK 3.7 (3.9) million is depreciation of right of use assets in accordance with IFRS 16 and SEK 0.2 (0.4) million is amortisation of licences attributable to the acquisition of VMA Life in 2020.



2021 | **Q1-Q4**SALES AND PROFITS



NORDIC COUNTRIES

In the Nordic countries, total revenues decreased by 6% to SEK 369.9 (392.0) million in Q1-Q4 2021 compared to the same period last year. This follows some sales growth in the Norwegian market. Performance in Denmark and Sweden was weaker and revenues decreased marginally during the year compared to the previous year. The Finnish market has seen a consistently weaker trend in 2021, losing ground compared to 2020. Zinzino has been focusing on the Finnish distributors and has taken steps to re-stimulate growth in the country. As a result, partner activity has picked up again and the decline in revenues has slowed in recent months. The downturn has continued in Iceland with low distributor activity and a reduced customer base this year.

Faun Pharma AS, the Group's subsidiary and manufacturing unit, has combined high internal production with continued growth in external production during the year, resulting in external sales increasing by 4% to SEK 62.6 (59.9) million compared to previous year.

Overall, total revenues in the Nordic countries, Zinzino and Faun combined, accounted for 32% (39%) of the Group's total revenues in the first six months of 2021.

BALTIC COUNTRIES

In the Baltic countries, total Q1-Q4 2021 cumulative revenues increased by 13% to SEK 79.2 (70.4) million compared to the same period last year. The growth was entirely attributable to Lithuania, where distributor activity has been consistently high with a large influx of new customers during the year. In Estonia, the decline stopped completely in the last months of the year, with increased distributor activity as the main underlying cause. On the other hand, there was a slight decline in sales in Latvia, where revenue during the year came mainly from the high proportion of repeat purchases of the company's products by existing customers. The region's total revenues represented 6% (6%) of the Group's total revenues in Q1-Q4 2021.

CENTRAL EUROPE

Consistently good growth in the region during the year. The experienced distributor organisation has run its operations with high levels of efficiency and a strong focus on the positive effects of the products. Through the work of the distributors, the region has built a strong customer base with a big interest in health that continues to grow. During the year, cumulative revenues compared to previous years increased by 30% to SEK 232.7 (179.6) million, following generally high activity among distributors. This represented 17% (16%) of the Group's total revenues in Q1-Q4 2021.

EASTERN EUROPE

Total cumulative revenues Q1-Q4 2021 increased by 24% to SEK 337.1 (272.3) million compared to the same period last year. Consistently strong growth in the region during the year. Growth was mainly driven by the Czech Republic, Slovakia and Poland with an increased customer base and subscription orders following high underlying distributor activity from existing and new distributors. Overall, the region accounted for 24% (24%) of the Group's total revenues in Q1-Q4 2021.

SOUTHERN & WESTERN EUROPE

The performance of the region has been consistently very strong in 2021 where all markets showed positive development. Total revenues Q1-Q4 2021 increased by 66% to SEK 147.1 (88.8) million. Very high activity in the growing distributor organisation in the UK and Ireland, where the digital meeting culture has been gradually replaced by face-to-face interactions during the year as pandemic restrictions have slowly eased. The high level of distributor activity has quickly resulted in a large customer base with growing subscription revenues. At the same time, the healthy development has continued in the Netherlands with a large customer base and high growth of new customers driven by the strong distributor organisation. In France, Italy and Spain, the newly appointed local sales managers have stimulated distributor activity and sales growth. At the same time, growth has also picked up in neighbouring markets such as Greece, Cyprus and Slovenia. The region together accounted for 11% (8%) of the Group's total revenues in Q1-Q4 2021.

NORTH AMERICA

Revenues in North America increased during the year by 24% to SEK 51.3 (41.3) million compared to the same period last year. Overall, the region has shown positive development during the year with good growth, mainly driven by an increase in customer subscriptions and related orders. The underlying growth from the activity of existing and new distributors with an extra emphasis on gaining new customer was the main underlying reason for the good customer subscription performance. Zinzino will continue to adapt its digital platforms to North America, develop the collaboration with Life Leadership and support the distributor organisations to further stimulate the growth rate. North America accounted for 4% (4%) of the Group's total revenues in Q1-Q4 2021.

APAC

The region's revenues increased during the year by 162% to SEK 89.7 (34.3) million compared to the same period last year. Consistently high activity among new and existing distributors, but pandemic restrictions and shutdowns have nonetheless slowed sales performance in the region to some extent. At the same time, the establishment team is working intensively to complete all the processes required to open more markets under the Zinzino banner. By the end of the year, Hong Kong, Taiwan and Malaysia had achieved full Zinzino market status and more markets are in the pipeline. As most of Zinzino's key distributors in Australia have connections in Asia, Zinzino sees great opportunities for synergies between the markets after the opening of sales in the APAC region. APAC accounted for 6% (3%) of the Group's total revenues in Q1-Q4 2021.

FRICA

The new region's revenue was fully attributed to the last quarter of 2021 and amounted to SEK 1.1 (0.0) million.

SALES PER PRODUCT SEGMENT Q1-Q4

The Zinzino Health product area increased Q1-Q4 2021 by 22% to SEK 1,197.8 (981.3) million and accounted for 87% (86%) of total revenues. The Zinzino Coffee product area decreased by 18% to SEK 25.2 (30.8) million, which corresponded to 2% (3%) of total revenue. External sales from Faun Pharma AS increased by 4% to SEK 62.6 (59.9) million, corresponding to 5% (5%) of total revenues. Other revenues amounted to SEK 85.0 (66.6) million, representing the remaining 6% (6%) of revenues for O1-Q4 2021.

GROWTH STRATEGY

A common feature of Zinzino's growth markets is that they are run by committed distributors working in a structured and active way. They have a wide network of contacts across the borders to neighbouring countries, and with the company's geographic expansion, also over longer distances. Work is carried out with a strong focus on Zinzino's Balance concept, which has been positively received by a large number of new customers in many new markets.

Zinzino is working long-term and investing considerable resources in the development of IT systems and marketing tools, which generate growth in both short and long term. When the company implements an expansion into a new market, this occurs mainly when the company's market analysis shows that there are good opportunities to establish an effective sales organisation locally. This is primarily achieved via contact to the already established sales organisations in neighbouring markets. This is precisely the reason for the good sales performance of the relatively newly established markets in Central and Southern Europe. These contacts can occasionally also carry across continents, which has been behind the launch in Australia and India, as well as the ongoing new establishment project in Asia. The establishment model follows the same concept for the various markets with customisation of websites and marketing materials in the local languages. Through the global webshop, Zinzino also covers more than 100 different countries around the world. This approach reduces the pressure on the organisation to open up full-scale markets, which requires significant internal resources that can now be fully allocated to the ongoing projects in Asia, Africa and Europe.

Sales **1,370.6** (1,138,6)

SALES PER PRODUCT AREA Q1-Q4



HEALTH 2021; SEK 1,197,8 (981,3) million



COFFEE 2021; SEK 25.2 (30.8) million



OTHER INCOME 2021; SEK 85.0 (66.6) million




FAUN 2021; SEK 62.6 (59.9) million

RESULTS AND FINANCIAL POSITION Q1-Q4

PROFITS

Accumulated gross profit Q1-Q4 amounted to SEK 427.5 (348.6) million and the gross profit margin to 31.2% (30.6%). Gross profitability improved progressively during the year through price adjustments and changes in the remuneration model for distributors, although a temporary increase in costs related to this year's Black Friday promotion dampened the impact somewhat. Internal production has also been streamlined. Overall, the measures have resulted in an overall margin improvement on cost of goods sold. Adjusted gross profit amounted to SEK 427.5 (326.4) million and the adjusted gross margin to 31.2% (28.7%). The adjustment related to the one time effect of the change of the distributor reimbursement in 2020. The positive effect of the change in accounting amounted to SEK 22.2 million and occurred in the first quarter of 2020.



Operating profit before depreciation/amortisation amounted to SEK 137.6 (108.5) million. The group's EBITDA margin was 10.0% (9.5%). Adjusted operating profit before depreciation/amortisation amounted to SEK 137.6 (86.3) million and the adjusted EBITDA margin to 10.0% (7.6%). The margin improvement is achieved through the economies of scale created by consistently improved efficiencies in IT systems, logistics and the organisation as a whole.


Operating profit amounted to SEK 116.0 (86.6) million and the operating margin was 8.5% (7.6%). Adjusted operating profit amounted to SEK 116.0 (64.4) million and the adjusted operating margin to 8.5% (5,7%). Profit before tax totalled SEK 114.9 (85.0) million and net profit was SEK 89.7 (66.3) million. Adjusted profit before tax amounted to SEK 114.9 (62.8) million and adjusted net profit to SEK 89.7 (48.9) million.

INVENTORIES

The Group's total inventories on the balance sheet date amounted to SEK 158.7 (126.9) million, where the company generally has higher inventory levels to ensure deliveries. At the same time, the company has built up inventory levels in the APAC region as well as in India and South Africa to ensure efficient deliveries to the rapidly growing demand in the respective regions.

FINANCIAL POSITION

On the balance sheet date, cash totalled SEK 235.7 (143.2) million. Cash flow of the period from operating activities totalled SEK 153.5 (97.3) million. The Group's equity/assets ratio was 25% (20%). Equity in the Group at the end of the period amounted to SEK 151.7 (94.7) million, corresponding to SEK 4.52 (2.88) per share. The assessment of the Board of Directors is that liquid assets are still at a satisfactory level and that the Group's positive cash flow from operating activities will ensure liquidity in the Group for the foreseeable future.





GROUP REPORT SUMMARY OF FINANCIAL POSITION

Amounts in SEK thousands	01/10/2021 31/12/2021	01/10/2020 31/12/2020	01/01/2021 31/12/2021	01/01/2020 31/12/2020
Net sales	372,571	323,128	1,288,481	1,074,448
Other revenue	27,905	17,282	80,635	63,707
Own work capitalised	757	-	1,497	490
Goods for resale and other direct costs	-287,484	-230,179	-943,093	-790,090
Gross profit	113,749	110,231	427,520	348,555
External operating expenses	-48,441	-41,021	-154,211	-134,926
Personnel costs	-38,861	-31,773	-135,739	-105,093
Depreciation/amortisation	-5,603	-6,481	-21,602	-21,958
Operating profit	20,844	30,956	115,968	86,578
Net financial income/expense	-330	196	-1,050	-1,563
Tax	-6,014	-7,122	-25 208	-18,689
PROFIT/LOSS FOR THE PERIOD	14,500	24,030	89,710	66,326
Items that may be reclassified to profit/loss for the Currency exchange differences upon conversion of for- eign subsidiaries		-603	5 029	-5 546
eign subsidiaries	2,386	-603	5,029	-5,546
Other comprehensive profit/loss for the period	2,386	-603	5,029	-5,546
TOTAL COMPREHENSIVE PROFIT/LOSS FOR THE PERIOD	16,886	23,427	94,739	60,780
Profit/loss for the period attributable to:				
Parent company's shareholders	14,335	23,364	86,204	64,477
Non-controlling interest	165	666	3,506	1,849
TOTAL	14,500	24,030	89,710	66,326
Total comprehensive profit/loss for the period attributable to:				
Parent company's shareholders	16,721	22,761	91,233	58,931
Non-controlling interest	165	666	3,506	1,849
TOTAL	16,886	23,427	94,739	60,780
Earnings per share, calculated on the profit/loss fo company's shareholders: Amounts in SEK	r the period att	ributable to t	he parent	
Earnings per share before dilution	0.43	0.71	2.57	1.96
Earnings per share after dilution	0.41	0.67	2.46	1.88

GROUP REPORT SUMMARY OF FINANCIAL POSITION

Other intangible fixed assets 22,904 15 Equipment, tools and installations 11,047 6 Right-of-Use Assets 38,063 43 Financial fixed assets 5,094 3 Total fixed assets 117,739 109 Current assets 117,739 109 Current receivables 57,950 66 Pre-paid costs and accrued revenues 35,128 36 Cash and bank balances 235,732 14 Total current assets 487,467 373 Total current assets 487,467 373 Equity 5 36 Share capital 3,370 3 Other contributed capital 35,830 2 Retained earnings including profit/loss for the period 112,518 66 Total equity 151,718 94 Long-term liabilities 25,025 36 Deferred tax liability 1,387 36 Other long-term liabilities 4,516 56	5,593 1,225 5,831 5,553 6,698 ,900
Other intangible fixed assets 22,904 15 Equipment, tools and installations 11,047 6 Right-of-Use Assets 38,063 43 Financial fixed assets 5,094 3 Total fixed assets 117,739 109 Current assets 117,739 109 Current receivables 57,950 66 Pre-paid costs and accrued revenues 35,128 36 Cash and bank balances 235,732 14 Total current assets 487,467 373 Total current assets 487,467 373 Equity 5 36 Share capital 3,370 3 Other contributed capital 35,830 2 Retained earnings including profit/loss for the period 112,518 66 Total equity 151,718 94 Long-term liabilities 25,025 36 Deferred tax liability 1,387 36 Other long-term liabilities 4,516 56	,225 ,831 ,553 ,698
Other intangible fixed assets 22,904 15 Equipment, tools and installations 11,047 6 Right-of-Use Assets 38,063 43 Financial fixed assets 5,094 3 Total fixed assets 117,739 109 Current assets 117,739 109 Current receivables 57,950 66 Pre-paid costs and accrued revenues 35,128 36 Cash and bank balances 235,732 14 Total current assets 487,467 373 Total current assets 487,467 373 Equity 5 36 Share capital 3,370 3 Other contributed capital 35,830 2 Retained earnings including profit/loss for the period 112,518 66 Total equity 151,718 94 Long-term liabilities 25,025 36 Deferred tax liability 1,387 4 Other long-term liabilities 4,516 5	,225 ,831 ,553 ,698
Equipment, tools and installations 11,047 6 Right-of-Use Assets 38,063 43 Financial fixed assets 5,094 3 Total fixed assets 117,739 109 Current assets 117,739 109 Inventories 158,657 126 Current receivables 57,950 66 Pre-paid costs and accrued revenues 35,128 36 Cash and bank balances 235,732 14 Total current assets 487,467 373 TOTAL ASSETS 605,206 483 Equity 3,370 3 Share capital 3,370 3 Other contributed capital 35,830 2 Retained earnings including profit/loss for the period 112,518 6 Total equity 151,718 94 Long-term liabilities 25,025 36 Leasing liabilities 25,025 36 Deferred tax liability 1,387 36 Other long-term liabilities 4,516 6	,831 ,553 ,698
Financial fixed assets 5,094 3 Total fixed assets 117,739 109 Current assets 158,657 126 Inventories 158,657 126 Current receivables 57,950 66 Pre-paid costs and accrued revenues 35,128 36 Cash and bank balances 235,732 14 Total current assets 487,467 373 Total current assets 605,206 483 Equity 3,370 3 Share capital 3,370 3 Other contributed capital 35,830 2 Retained earnings including profit/loss for the period 112,518 66 Total equity 151,718 94 Long-term liabilities 25,025 3 Deferred tax liability 1,387 9 Other long-term liabilities 4,516 9	,698
Current assets 117,739 109 Current assets 158,657 126 Inventories 158,657 126 Current receivables 57,950 66 Pre-paid costs and accrued revenues 35,128 36 Cash and bank balances 235,732 14 Total current assets 487,467 373 Equity Share capital 3,370 3 Other contributed capital 35,830 2 Retained earnings including profit/loss for the period 112,518 66 Total equity 151,718 94 Long-term liabilities 25,025 36 Leasing liabilities 25,025 36 Deferred tax liability 1,387 60 Other long-term liabilities 4,516 5	
Current assets Inventories 158,657 126 Current receivables 57,950 66 Pre-paid costs and accrued revenues 35,128 36 Cash and bank balances 235,732 14 Total current assets 487,467 373 Equity 5 5 Share capital 3,370 35 Other contributed capital 35,830 2 Retained earnings including profit/loss for the period 112,518 66 Total equity 151,718 94 Long-term liabilities 25,025 34 Leasing liabilities 25,025 34 Other long-term liabilities 4,516 5	,900
Inventories 158,657 126 Current receivables 57,950 66 Pre-paid costs and accrued revenues 35,128 36 Cash and bank balances 235,732 143 Total current assets 487,467 373 ***TOTAL ASSETS 605,206 483 ***Equity ***Share capital 3,370 3 Other contributed capital 35,830 2 Retained earnings including profit/loss for the period 112,518 63 Total equity 151,718 94 ***Long-term liabilities** 25,025 34 Leasing liabilities 25,025 34 Deferred tax liability 1,387 Other long-term liabilities 4,516 5	
Current receivables 57,950 66 Pre-paid costs and accrued revenues 35,128 36 Cash and bank balances 235,732 145 Total current assets 487,467 373 TOTAL ASSETS 605,206 483 Equity Share capital 3,370 3 Other contributed capital 35,830 20 Retained earnings including profit/loss for the period 112,518 63 Total equity 151,718 94 Long-term liabilities 25,025 34 Leasing liabilities 25,025 34 Deferred tax liability 1,387 Other long-term liabilities 4,516 5	
Pre-paid costs and accrued revenues 35,128 36 Cash and bank balances 235,732 143 Total current assets 487,467 373 Fquity Share capital 3,370 3 Other contributed capital 35,830 22 Retained earnings including profit/loss for the period 112,518 63 Total equity 151,718 94 Long-term liabilities 25,025 34 Leasing liabilities 25,025 34 Deferred tax liability 1,387 34 Other long-term liabilities 4,516 5	,948
Cash and bank balances235,732143Total current assets487,467373TOTAL ASSETS605,206483Equity Share capital3,3703Other contributed capital35,8302Retained earnings including profit/loss for the period112,51863Total equity151,71894Long-term liabilities25,02534Leasing liabilities25,02534Deferred tax liability1,38734Other long-term liabilities4,5165	,536
Total current assets487,467373TOTAL ASSETS605,206483Equity Share capital Other contributed capital Retained earnings including profit/loss for the period3,3703 35,8302 27Total equity151,71894Long-term liabilities Leasing liabilities Deferred tax liability Other long-term liabilities25,02534 4,516Other long-term liabilities4,5165 5	,791
TOTAL ASSETS605,206483EquityShare capital3,3703Other contributed capital35,8302Retained earnings including profit/loss for the period112,51863Total equity151,71894Long-term liabilities25,02534Deferred tax liability1,387Other long-term liabilities4,5165	3,218
Equity Share capital 3,370 3 Other contributed capital 35,830 2 Retained earnings including profit/loss for the period 112,518 63 Total equity 151,718 94 Long-term liabilities Leasing liabilities 25,025 34 Deferred tax liability 1,387 Other long-term liabilities 4,516 55	,493
Share capital 3,370 Start Capital 35,830 20 Start Capital St	,393
Share capital 3,370 Start Capital 35,830 20 Start Capital St	
Other contributed capital 35,830 27 Retained earnings including profit/loss for the period 112,518 63 Total equity 151,718 94 Long-term liabilities Leasing liabilities 25,025 34 Deferred tax liability 1,387 Other long-term liabilities 4,516 55	,305
Retained earnings including profit/loss for the period 112,518 63 Total equity 151,718 94 Long-term liabilities Leasing liabilities 25,025 34 Deferred tax liability 1,387 Other long-term liabilities 4,516 55	7,507
Total equity151,71894Long-term liabilities25,02534Deferred tax liability1,387Other long-term liabilities4,5165	,307
Leasing liabilities25,02534Deferred tax liability1,387Other long-term liabilities4,5165	,663
Leasing liabilities25,02534Deferred tax liability1,387Other long-term liabilities4,5165	
Deferred tax liability 1,387 Other long-term liabilities 4,516	1,012
Other long-term liabilities 4,516	,012
	,329
Total long-term liabilities 30,928 39	,341
Current liabilities	
Accounts payable 44,251 54	,686
	2,311
	0,119
_	,007
	,266
	,389
TOTAL EQUITY AND LIABILITIES 605,206 483	

GROUP REPORT SUMMARY OF CHANGES IN EQUITY

Amounts in SEK thousands	Share capital	Ongoing rights issue	Other contribu- ted capital	Tran- slation reserves	Retained earnings including profit/loss for the period	Total	Non-control- ling interest	Total Equity
Opening balance	2 250		42.004	4 425	45 500	22.047	7 074	40 207
01/01/2020 Drofit /loss for the period	3,258	-	12,804	1,435	15,520 64,477	33,017 64,477	7,271 1,849	40,287 66,326
Profit/loss for the period	-	-	-	-	04,477	04,477	1,049	00,320
Other comprehensive profit/loss for the period			_	-6,707	_	-6,707		-6,707
Share repurchase	_	_	_	-	-669	-669	_	-669
Change of the minority	_	_	_	_	1,882	1,882	-1,882	
Rights issue	47	31	14,673	_	-	14,751	-	14,751
Issued warrants	-	-	11,075	_	3,662	3,662		3,662
Dividends			_		-22,987	-22,987		-22,987
Closing balance	3,305	31	27,477	-5,272	61,885	87,426	7,238	94,663
31/12/2020	3,303	31	27,477	-5,272	01,883	67,420	7,230	94,003
Opening balance								
01/01/2021	3,305	31	27,477	-5,272	61,885	87,426	7,238	94,663
Profit/loss for the period	-	-	-	-	86,204	86,204	3,506	89,710
Other comprehensive								
profit/loss for the period	-	-	-	4,468	-	4,468	-	4,468
Share repurchase	-	-	-	-	-1,412	-1,412	-	-1,412
Change of the minority	-	-	-	-	101	101	-101	-
Rights issue	65	-24	8,346	-	-	8,387	-	8,387
Dividends	-	-	-	-	-42,120	-42,120	-1,978	-44,098
Closing balance 31/12/2021	3,370	7	35,823	-804	104,658	143,054	8,665	151,718

GROUP REPORT SUMMARY OF CASH FLOWS

Amounts in SEK thousands	01/10/2021 31/12/2021	01/10/2020 31/12/2020	01/01/2021 31/12/2021	01/01/2020 31/12/2020
Operating activities				
Profit/loss before financial items	20,844	30,956	115,968	86,578
Depreciation and amortisation/write-downs	5,603	6,481	21,602	21,958
Currency fluctuations	-2,685	1,023	-5,743	2,679
Total	23,762	38,460	131,827	111,215
Interest received	64	11	383	91
Interest paid	-393	-42	-1,432	-1,654
Tax paid	-5,283	-477	-20,521	-4,314
Total	-5,612	-508	-21,570	-5,877
Cash flow from operating activities before changes in operating capital	18,150	37,952	110,257	105,338
Cash flow from changes in operating capital				
Change in inventories	11,408	3,161	-31,709	-36,560
Change in current receivables	-6,126	-11,573	10,252	-70,259
Change in current liabilities	36,076	3,319	64,692	98,793
Total	41,358	-5,093	43,235	-8,026
Cash flow from operating activities	59,508	32,859	153,492	97,312
Investment activity				
Investments in intangible fixed assets	-1,973	-	-5,836	-2,321
Investments in tangible fixed assets	-852	-523	-3,838	-2,561
Investments in financial fixed assets	-80	-668	-2,308	-4,502
Cash flow from investment activities	-2,905	-1,191	-11,982	-9,384
Financing activities				
Amortisation of lease liabilities attributable to lease	4.022	5.606	45.262	42.424
agreements Issuance of options	-4,022	-5,686 262	-15,263	-13,424 2,140
Rights issue	225	3,837	8,387	12,724
Dividends		3,037	-42,120	-22,987
Cash flow from financing activities	-3,797	-1,587	-48,996	-21,547
CASH FLOW FOR THE PERIOD	52,806	30,081	92,514	66,381
Cash and cash equivalents at start of period	182,926	113,137	143,218	76,837
Cash and cash equivalents at end of period	235,732	143,218	235,732	143,218
Change in cash and cash equivalents	52,806	30,081	92,514	66,381

PARENT COMPANY REPORT

SUMMARY INCOME STATEMENT

Amounts in SEK thousands	01/10/2021 31/12/2021	01/10/2020 31/12/2020	01/01/2021 31/12/2021	01/01/2020 31/12/2020
Net sales	39,439	58,105	118,190	73,766
Other revenue	3,860	5,108	22,291	10,423
Goods for resale and other direct costs	-32,591	-38,458	-103,744	-43,768
Gross profit	10,708	24,755	36,737	40,421
External operating expenses	-7,038	-6,547	-26,326	-18,397
Depreciation/amortisation	-157	-142	-606	-421
Operating profit	3,513	18,066	9,805	21,603
Net financial income/expense	58,039	28,282	61,277	29,292
Tax	-639	-5,067	-2,196	-5,067
PROFIT/LOSS FOR THE PERIOD	60,913	41,281	68,886	45,828

There are no items in the parent company reported as other comprehensive profit/loss, so the total comprehensive profit/loss matches the profit/loss for the period.

PARENT COMPANY REPORT SUMMARY OF FINANCIAL POSITION

Amounts in SEK thousands	31/12/2021	31/12/2020
Fixed assets		
Intangible fixed assets	4,910	1,886
Tangible fixed assets	31	
Financial fixed assets	104,330	100,009
Total fixed assets	109,271	101,895
Current assets		
Current receivables	2,252	57
Intra-group receivables	24,659	18,200
Pre-paid costs and accrued revenues	2,331	2,941
Cash and bank balances	4,471	7,091
Total current assets	33,713	28,289
TOTAL ASSETS	142,984	130,184
Equity		
Restricted equity		
Share capital	3,370	3,305
Ongoing rights issue	7	31
Fund for development expenditures	4,910	1,886
Unrestricted equity		
Share premium reserve	45,154	36,808
Retained earnings (including profit/loss for the year)	52,438	28,696
Total equity	105,879	70,726
Long-term liabilities		
Long-term liabilities	4,070	4,913
Intra-group long-term liabilities	15,476	15,476
Total long-term liabilities	19,546	20,389
Current liabilities		
Tax liabilities	1,727	5,067
Intra-group current liabilities	2,512	22,265
Other current liabilities	11,902	10,866
Accrued costs and deferred revenues	1,418	871
Total current liabilities	17,559	39,069
TOTAL EQUITY AND LIABILITIES	142,984	130,184

PARENT COMPANY REPORT SUMMARY OF CHANGES IN EQUITY

Amounts in SEK thousands	Share capital	Ongoing rights issue	Fund for develop- ment ex- penditures	Share premium reserve	Retained earnings in- cluding pro- fit/loss for the period	Total Equity
Opening balance 01/01/2020	3,258	-	1,129	22,138	2,734	29,259
Profit/loss for the period	-	-	-	-	45,828	45,828
Internally generated intangible assets	-	-	757	-	-757	-
Rights issue	47	31	-	14,670	-	14,748
Issued warrants	-	-	-	-	3,878	3,878
Dividends	-	-	-	-	-22,987	-22,987
Closing balance 31/12/2020	3,305	31	1,886	36,808	28,696	70,726
Opening balance 01/01/2021	3,305	31	1,886	36,808	28,696	70,726
Profit/loss for the period	-	-	-	-	68,886	68,886
Internally generated intangible assets	-	-	3,024	-	-3,024	-
Rights issue	65	-24	-	8,346	-	8,387
Dividends	-	-	-	-	-42,120	-42,120
Closing balance 31/12/2021	3,370	7	4,910	45,154	52,438	105,879

PARENT COMPANY REPORT SUMMARY OF CASH FLOWS

Amounts in SEK thousands	01/10/2021 31/12/2021	01/10/2020 31/12/2020	01/01/2021 31/12/2021	01/01/2020 31/12/2020
Operating activities				
Profit/loss before financial items	3,513	18,066	9,805	21,603
Depreciation and amortisation/write-downs	157	142	606	421
Currency fluctuations	-2,001	39	-1,329	-950
Total	1,669	18,247	9,082	21,074
Interest received	110	-	565	23
Interest paid	-1	-1	-3	-2
Tax paid	-128	-	-5,536	-
Total	-19	-1	-4,974	21
Cash flow from operating activities before changes in operating capital	1,650	18,246	4,108	21,095
Cash flow from changes in operating capital				
Change in current receivables	-2,178	-223	-46	-2,029
Change in current liabilities	129	-13,999	32,282	2,523
Cash flow from operating activities	-399	4,024	36,344	21,589
Investment activity				
Investments in intangible fixed assets	-906	-649	-3,107	-1,179
Investments in tangible fixed assets	-	-	-38	-
Investments in financial fixed assets	-84	-898	-4,321	-5,237
Cash flow from investment activities	-990	-1,547	-7,466	-6,416
Financing activities				
Issuance of options	-	-14	-	8
Rights issue	225	3,837	8,387	12,724
Dividends received	-	-	2,235	-
Dividends	-	-	-42,120	-22,987
Cash flow from financing activities	198	3,823	-31,498	-10,255
CASH FLOW FOR THE PERIOD	-1,164	6,300	-2,620	4,918
Cash and cash equivalents at start of period	5,635	791	7,091	2,173
Cash and cash equivalents at end of period	4,471	7,091	4,471	7,091
Change in cash and cash equivalents	-1,164	6,300	-2,620	4,918

NOTE 1

SEGMENT INFORMATION

Description of segments and main activities:

A business segment is part of a company which carries out business activities from which it can obtain revenue and incur costs, the contribution of which is regularly reviewed by the company's highest executive decision-maker, and for which there is independent financial information.

The company's reporting of business segments is in line with the internal reporting to the highest executive decision-maker. The highest executive decision-maker is the position that assesses the earnings of the business segment and decides on the allocation of resources. The CEO is the highest executive decision-maker together with the Group CFO and the controller manager. Together, they form the strategic steering group at Zinzino. The strategic steering group assesses the operations based on the two business segments Zinzino and Faun. The steering group mainly uses profit/loss before financial items in the assessment of business segment earnings. Segment reporting is divided based on the main segment of the business "Zinzino", which includes the product areas Health, Coffee and Other revenue.

The Health product area includes the Balance, Immune Supplement, Skin Care and Weight Control sub-areas. The product area Coffee is also called Beverages and includes espresso machines, coffees, teas and accessories. Other revenue consists mainly of freight and reminder fees. All sales are made via the Zinzino's website www.zinzino.com with the help of the company's independent sales organisation, which goes under the names of distributors or Partners.

The second segment refers to the Norwegian production unit Faun Pharma AS, known as "Faun", which carries out production and sales to external customers not under Zinzino's standard sales concept. Sales from Faun comprise exclusively contract production of food supplements to different customers. The largest external customers include Life and Proteinfabrikken AS. In Q3 and Q4 2020, the VMA Life segment included sales from the operations in Singapore, Malaysia, Taiwan and Thailand that were added in connection with the acquisition of VMA Life. In 2021, sales in these countries were included in the Zinzino segment. The comparative figures for 2020 have been recalculated in accordance with the updated segment structure and VMA Life has been allocated to the Zinzino segment.

Segment revenues and earnings

Total revenues and earnings before financial items is the result metric reported to the strategic steering group at Zinzino. An analysis of the group's revenues and earnings for the two reporting operating segments is set out below:

- 7inzino
- · Faun Pharma AS

The strategic steering group mainly uses adjusted earnings before interest and tax and operating earnings (see below) to assess the business segment profit/loss.

			Group	
Oct-Dec 2021	Zinzino	Faun	elimination	Total Group
Net sales	358,690	23,610	-9,729	372,571
Other revenue	26,486	1,419	-	27,905
Own work capitalised	757	-	-	757
Goods for resale and other direct costs	-280,224	-16,989	9,729	-287,484
Gross profit	105,709	8,040	-	113,749
External operating expenses	-45,946	-2,495	-	-48,441
Personnel costs	-31,144	-7,717	-	-38,861
EBITDA	28,619	-2,172	-	26,447
Depreciation/amortisation	-4,265	-1,338	-	-5,603
Operating profit	24,354	-3,510	-	20,844

			Group	
Oct-Dec 2020	Zinzino	Faun	elimination	Total Group
Net sales	305,438	41,133	-23,443	323,128
Other revenue	17,282	-	-	17,282
Own work capitalised	-	-	-	-
Goods for resale and other direct costs	-225,367	-28,255	23,443	-230,179
Gross profit	97,353	12,878	-	110,231
External operating expenses	-38,783	-2,238	-	-41,021
Personnel costs	-24,083	-7,690	-	-31,773
EBITDA	34,487	2,950	-	37,437
Depreciation/amortisation	-5,221	-1,260	-	-6,481
Operating profit	29,266	1,690	-	30,956

Jan-Dec 2021	Zinzino	Faun	Group elimination	Total Group
Net sales	1,227,344	161,604	-100,467	1,288,481
Other revenue	79,216	1,419	-	80,635
Own work capitalised	1,497	-	-	1,497
Goods for resale and other direct costs	-931,838	-111,722	100,467	-943,093
Gross profit	376,219	51,301	-	427,520
External operating expenses	-146,323	-7,888	-	-154,211
Personnel costs	-108,724	-27,015	-	-135,739
EBITDA	121,172	16,398	-	137,570
Depreciation/amortisation	-16,506	-5,096	-	-21,602
Operating profit	104,666	11,302	-	115,968
			Group	
Jan-Dec 2020	Zinzino	Faun	elimination	Total Group
Net sales	1,014,525	149,685	-89,762	1,074,448
Other revenue	63,707	-	-	63,707
Own work capitalised	490	-	-	490
Goods for resale and other direct costs	-775,225	-104,627	89,762	-790,090
Gross profit	303,497	45,058	-	348,555
External operating expenses	-128,031	-6,895	-	-134,926
Personnel costs	-80,659	-24,434	-	-105,093
EBITDA	94,807	13,729	-	108,536
Depreciation/amortisation	-17,082	-4,876	-	-21,958
Operating profit	77,725	8,853	-	86,578

NOTE 2 **NET TURNOVER**

Revenues

Sales between segments are carried out on market terms. As revenue from external parties is reported to the strategic steering group, they are valued in the same way as in the group's statement of comprehensive profit/loss.

Goods within Zinzino Health and Zinzino Coffee refer to sales to Zinzino's customers and distributors in the various sales markets through the online shop. The goods are sold mainly through subscriptions which run for a fixed period of 6 months and continue indefinitely until the customer terminates the subscription. All revenues are recognised when the goods are delivered to the customer in accordance with IFRS 15.

For more information regarding the products, see note 2.5.1 in the annual report 2020 regarding the principles of revenue recognition.

External goods Faun refers to goods produced on contract for an external customer. Revenue is recognised when the goods are delivered to the customer in accordance with IFRS 15, see note 2.5.1 in the 2020 annual report on revenue recognition principles.

Events and other services refer to revenue in connection with distributor conferences.

Oct-Dec 2021	Zinzino	Faun	Total Group
Net sales	358,690	13,881	372,571
Revenue from external customers	358,690	13,881	372,571
Goods within Zinzino Health	350,005	-	350,005
Goods within Zinzino Coffee	5,603	-	5,603
Sales of external goods Faun	-	13,881	13,881
Events and other services	3,082	-	3,082
TOTAL	358,690	13,881	372,571
TOTAL	330,050	,	
Oct-Dec 2020 Net sales	Zinzino 305,439	Faun 17,689	Total Group 323,128
Oct-Dec 2020	Zinzino	Faun	Total Group
Oct-Dec 2020 Net sales	Zinzino 305,439	Faun 17,689	Total Group 323,128
Oct-Dec 2020 Net sales Revenue from external customers	Zinzino 305,439 305,439	Faun 17,689	Total Group 323,128 323,128
Oct-Dec 2020 Net sales Revenue from external customers Goods within Zinzino Health	Zinzino 305,439 305,439 295,291	Faun 17,689 17,689	Total Group 323,128 323,128 295,291
Oct-Dec 2020 Net sales Revenue from external customers Goods within Zinzino Health Goods within Zinzino Coffee	Zinzino 305,439 305,439 295,291 7,774	Faun 17,689 17,689 - -	Total Group 323,128 323,128 295,291 7,774

Jan-Dec 2021	Zinzino	Faun	Total Group
Net sales	1,227,344	61,137	1,288,481
Revenue from external customers	1,227,344	61,137	1,288,481
Goods within Zinzino Health	1,197,856	-	1,197,856
Goods within Zinzino Coffee	25,168	-	25,168
Sales of external goods Faun	-	61,137	61,137
Events and other services	4,320	-	4,320
TOTAL	1,227,344	61,137	1,288,481
Jan-Dec 2020	Zinzino	Faun	Total Group
·		Faun	
Net sales	1,014,525	59,923	1,074,448
Revenue from external customers	1,014,525	59,923	1,074,448
Goods within Zinzino Health	981,389	-	981,389
Goods within Zinzino Coffee	30,762	-	30,762
Sales of external goods Faun	-	59,923	59,923
Events and other services	2,374	-	2,374
TOTAL	1,014,525	59,923	1,074,448

NOTE 3

TRANSACTIONS WITH RELATED PARTIES

Purchase of goods and services	01/10/2021 31/12/2021	01/10/2020 31/12/2020	01/01/2021 31/12/2021	01/01/2020 31/12/2020
Saele Invest och Consulting AS*	9,244	8,757	34,480	32,463
Oh Happy Day Aps**	1,725	1,612	6,724	6,067
TOTAL	10,969	10,369	41,204	38,530
Sales of goods and services	01/10/2021 31/12/2021	01/10/2020 31/12/2020	01/01/2021 31/12/2021	01/01/2020 31/12/2020
Sales of goods and services Sæle Invest & Consulting AS	*		• • = • = .	
	31/12/2021	31/12/2020	• • = • = .	

As of 31/12/2021, the debt to Saele Invest AS relating to sales commissions amounts to SEK 625 (665) thousand and to Oh Happy Day ApS to SEK 0 (0) thousand in the Group. All sales commissions paid to related parties with significant influence are calculated on the same commission plan and under the same terms as for all other distributors within Zinzino's global sales organisation.

^{*} Refers to sales commissions to/purchases from Saele Invest and Consulting AS which is controlled by Örjan Saele and who, through the company's shareholding in Zinzino AB, is defined as a person with significant influence.

^{**} Refers to sales commissions to Oh Happy Day, which is controlled by Peter Sörensen and who, through the company's shareholding in Zinzino AB, is defined as a person with significant influence.

^{***} Remuneration according to agreement for 75% of the company's establishment costs in Australia 2019/2020 from Oh Happy Day ApS. The receivable from the company as of 31/12/2021 amounts to SEK 2,251 (2,746) thousand.

NOTE 4 EARNINGS PER SHARE

	01/10/2021	01/10/2020	01/01/2021	01/01/2020
SEK	31/12/2021	31/12/2020	31/12/2021	31/12/2020
Earnings per share before dilution	0.43	0.71	2.57	1.96
Earnings per share after dilution	0.41	0.67	2.46	1.88
Earnings metric used in the calculation of earnings per share				
Earnings attributable to shareholders of the parent company used in the	14,335	23,364	86,204	64,477
calculation of earnings per share before and after dilution				
Number of shares:				
Weighted average number of ordinary shares in calculating earnings per share before dilution	33,696,682	33,043,438	33,551,514	32,860,203
Adjustment for calculation of earnings per share after dilution (of warrants).				
Weighted average number of ordinary shares and potential ordinary shares used as denominator in calculating earnings per share after dilution	35,100,145	34,776,661	35,092,535	34,300,203

NOTE 5 EVENTS AFTER THE END OF THE INTERIM PERIOD

No significant events for the company have occurred after the end of the reporting period as at 31 December 2021.

NOTE 6

FINANCIAL METRICS NOT DEFINED IN ACCORDANCE WITH IFRS

The company presents certain financial metrics in the interim report that are not defined in accordance with IFRS or the Annual Accounts Act. The company believes that these metrics provide valuable additional information to investors and the company's management as they allow the company's performance to be

evaluated. Since not all companies calculate financial metrics in the same way, these are not always comparable with the metrics used by other companies. These financial metrics should therefore not be considered as a substitute for metrics defined in accordance with IFRS.

ALTERNATIVE KEY FIGURES	DEFINITION	PURPOSE
Sales growth	The total revenue as a percentage change compared with the total revenue for the corresponding period of the previous year.	This metric is useful to follow as it shows the sales trend in the group.
Gross profit	Profit from total revenue less goods for resale.	This metric is useful to examine to see just the net sales during the period, which can be used in the income and cost analyses.
EBITDA	Operating profit before depreciation/ amortisation and write-downs.	This metric is relevant for creating an understanding of the company's operationa business, regardless of financing and depre ciation of fixed assets.
EBITDA margin:	EBITDA as a percentage of total revenues for the period.	This metric is relevant to create an understanding of operational profitability and as the metric excludes depreciation, this margin gives the stakeholders a clearer picture of the company's central profitability
Operating profit/loss (EBIT)	Operating profit/loss before financial items and taxes.	This metric illustrates profitability regard- less of the tax rate for corporation tax and irrespective of the company's financial struc- ture.
Net margin	Profit/loss for the period as a percentage of total revenues for the period.	This metric illustrates the company's profitability.
Equity per share before dilution	Equity in relation to the number of outstanding shares on the balance sheet date.	This metric measures the company's net value per share and shows whether the company is increasing the shareholders' capital over time.
Cash flow from operating activities	Cash flow from operational business including changes in the operating profit/loss.	This metric measures the cash flow the company generates before capital investments and cash flow attributed to the company's financing.
Equity/assets ratio	Equity in relation to the balance sheet total.	This metric is an indicator of the company's leverage to finance the company.
Adjusted EBITDA and Adjusted EBITDA margin	The definition of key figures described above, excluding items affecting comparability.	The metric is important for breaking down and creating an understanding of the effect regarding items affecting comparability.
Items affecting comparability	Items affecting comparability are reported separately in the financial statements when this is necessary to explain the group's results. "Items affecting comparability" means significant revenue or expense items that are reported separately due to the significance of their nature or amount.	The metric is significant for creating an understanding of items affecting comparability.

GOTHENBURG

28 FEBRUARY 2022

The Board of Directors and the CEO certify that the report for the period 1 January - 31 December 2021 gives a fair overview of the parent company and Group's operations, position and earnings and describes significant risks and uncertainties faced by the parent company and the companies in the group.

For more information, please call Dag Bergheim Pettersen, Chief Executive Officer, Zinzino AB.

Zinzino AB

Hulda Mellgrens gata 5 421 32 Västra Frölunda Email: info@zinzino.com Tel: +46 (0)31-771 71 50 Gothenburg, 28 February 2022

Hans Jacobsson

Board Chair

Pierre Mårtensson

Board Member

Ingela Nordenhav
Board Member

Staffan Hillberg Board Member **Anna Frick** Board Member **Dag Bergheim Pettersen**Chief Executive Officer

AUDITOR'S AUDIT REPORT

This interim report has not been the object of a review by the company's auditors.

